Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas

Douglas S. Hawkins, Sheri L. Spunt, Stephen X. Skapek

Research output: Contribution to journalReview articlepeer-review

117 Scopus citations


In the US, approximately 850-900 children are diagnosed each year with soft tissue sarcomas (STS). Key findings from recent Children's Oncology Group (COG) clinical trials include safe reduction in therapy for low risk rhabdomyosarcoma (RMS), validation of FOXO1 fusion as a prognostic factor, a modest improvement in outcome for high-risk RMS, and a biologically designed non-cytotoxic therapy for pediatric desmoid tumor. Planned Phase 2 trials include targeted agents for VEGF/PDGF, mTOR, and IGF-1R for children with RMS and VEGF for children with non-RMS STS (NRSTS). For RMS, COG Phase 3 trials potentially will explore VEGF/mTOR inhibition or chemotherapy interval compression. For NRSTS, a COG Phase 3 trial will explore VEGF inhibition.

Original languageEnglish (US)
Pages (from-to)1001-1008
Number of pages8
JournalPediatric Blood and Cancer
Issue number6
StatePublished - Jun 2013


  • Children
  • Malignancies
  • Non-rhabdomyosarcoma soft tissue sarcoma
  • Rhabdomyosarcoma
  • Sarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas'. Together they form a unique fingerprint.

Cite this